A short hepatitis C virus NS5A peptide expression by AAV vector modulates human T cell activation and reduces vector immunogenicity

Viral vector-mediated gene therapies have the potential to treat many human diseases; however, host immune responses against the vector and/or the transgene pose a safety risk to the patients and can negatively impact product efficacy. Thus, novel strategies to reduce vector immunogenicity are criti...

Descripción completa

Detalles Bibliográficos
Autores principales: Colon-Moran, Winston, Baer, Alan, Lamture, Gauri, Stapleton, Jack T., Fischer, Joseph W., Bhattarai, Nirjal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091046/
https://www.ncbi.nlm.nih.gov/pubmed/34759330
http://dx.doi.org/10.1038/s41434-021-00302-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091046/
https://www.ncbi.nlm.nih.gov/pubmed/34759330
http://dx.doi.org/10.1038/s41434-021-00302-5

Ejemplares similares